Quizartinib has been approved by the FDA for use with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy after consolidation chemotherapy, to treat adults with newly diagnosed acute myeloid leukemia that is FLT3-ITD positive, as detected by an FDA-approved test.
Patients with synchronous metastatic renal cell carcinoma experienced worse outcomes with first line immune-checkpoint inhibitors-based combinations vs those with metachronous disease.
Third-line lisocabtagene maraleucel induced a response in 97% of patients with relapsed or refractory follicular lymphoma.
Lazertinib reduced the risk of progression by 55% in patients with EGFR-mutated advanced non–small cell lung cancer compared with gefitinib.
Final overall survival analysis highlights benefit of lenvatinib plus pembrolizumab vs sunitinib in the treatment of patients with advanced renal cell carcinoma.
Trastuzumab deruxtecan elicited a confirmed objective response rate of 42% in patients with HER2-positive gastric or gastroesophageal junction cancer, according to findings from the phase 2 DESTINY-Gastric02 trial.
Adjuvant pembrolizumab improved disease-free survival outcomes vs placebo across subgroups of patients with clear cell renal cell carcinoma in the KEYNOTE-564 study.
The onset of skeletal events and events that affect health-related quality of life were delayed with the addition of lutetium Lu 177 vipivotide tetraxetan to standard of care for patients with metastatic castration-resistant prostate cancer.
Among 32 patients, 66% experienced a prostate-specific antigen response rate of at least 50%.
Findings from the phase 1b cohort of the KRYSTAL-1 trial underscore the intracranial permeation of the KRAS G12C inhibitor adagrasib for patients with non–small cell lung cancer with untreated central nervous system metastases.
Intensified doxorubicin, bleomycin, vinblastine, dacarbazine, and granulocyte colony–stimulating factor (ABVD) was associated with a 56% reduction in the relative risk of 3-year progression, relapse, or death.
Glofitamab monotherapy led to a 63.6% overall response rate in heavily pretreated patients with Richter syndrome.
By 3 months postsurgery, most older patients with colon or rectal cancer had achieved functional recovery.
Patients with oropharyngeal squamous cell carcinoma who received primary radiotherapy or surgery demonstrated similar long-term patient-reported outcomes.
On-pathway regimens are associated with lower costs, and slightly higher emergency department visits and adverse event rates in cancer care.
The rate of pathologic complete responses with enfortumab vedotin was 36.4% among patients with muscle-invasive bladder.
Pirtobrutinib was associated with a 19.6-month median progression-free survival in patients with heavily pretreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
The complete response or complete response with incomplete bone marrow recovery rate was 61% for patients with chronic lymphocytic leukemia and high-risk disease.
Experts share insights on standard work-up and staging practices for a patient with newly diagnosed bladder cancer.
Expert panelists unpack a patient's bladder cancer presentation, evaluating the presence of typical signs and symptoms that could lead to a diagnosis.
The FDA has granted priority review to the biologics license application for zolbetuximab as a treatment for patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Among patients with lung oligometastases, no significant differences in overall or disease-free survival were observed with single- and multi-fraction stereotactic ablative body radiotherapy.
A prostate stem cell antigen-directed CAR T-cell therapy agent showed preliminary efficacy in patients with metastatic castration-resistant prostate cancer.
The National Comprehensive Cancer Network has updated their guidelines on high-dose methotrexate and glucarpidase.
The FDA has approved a ready-to-dilute cyclophosphamide injection.
Arletta Jackson, RN, MSN, explains the concept of patient-centric infusion and how it benefits both nurses and patients.
The median overall survival with intra-arterial gemcitabine was 15.7 months vs 10.1 months with intravenous gemcitabine and nab-paclitaxel.
Manufacturers are pulling the pralsetinib indication for patients with medullary thyroid cancer. It is still under investigation as a treatment option for patients with non–small cell lung cancer.
Patients with advanced urothelial carcinoma who received avelumab reported any-grade treatment-related adverse events at a rate of 78.2%.
Patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor achieved preliminary responses with the CD20-targeted CAR T-cell therapy MB-106.
